Ligand Pharmaceuticals LGND Unrealized Gains on Investments
Unrealized Gains on Investments at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's unrealized gains on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's unrealized gains on investments?
- Ligand Pharmaceuticals (LGND) reported unrealized gains on investments of $60.71M in Q1 2026.
- How has Ligand Pharmaceuticals's unrealized gains on investments changed year-over-year?
- Ligand Pharmaceuticals's unrealized gains on investments increased by 1667.3% year-over-year, from $3.44M to $60.71M.
- What is the long-term trend for Ligand Pharmaceuticals's unrealized gains on investments?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's unrealized gains on investments has grown at a 114.6% compound annual growth rate (CAGR), from $1.3M to $59.2M.